Author

A. P. Khandhar

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 5 Organism:mouse· 4 Research Focus:drug response / drug discovery· 3 Organism:rat· 2 Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1 Organism:non-human primate· 1

Frequent Co-Authors

J. Archer· 4 shared D. H. Fuller· 3 shared D. W. Hawman· 3 shared H. Feldmann· 3 shared J. Erasmus· 3 shared M. Gale· 3 shared P. Berglund· 3 shared S. G. Reed· 3 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

J. Archer

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

ImmunologybioRxivMay 23, 2023

Accelerated prime-and-trap vaccine regimen in mice using repRNA-based CSP malaria vaccine

Z. MacMillen, K. Hatzakis, A. Simpson…·M. Avril

This paper develops an accelerated prime-and-trap vaccine regimen in mice using repRNA-based CSP malaria vaccine that provides sterile protection with a single day regimen.

DOI 10.1038/s41541-023-00799-4

mouseexperimental assay

𝕏 PostBluesky

ImmunologybioRxivPreprintFeb 23, 2022

RNA-based vaccine demonstrates prophylactic efficacy against Mycobacterium tuberculosis challenge in a mouse model

S. E. Larsen, J. H. Erasmus, V. A. Reese…·R. N. Coler

This study evaluates two TB vaccine platforms in mice, showing both reduce bacterial burden, with RNA-based vaccines showing greater efficacy in combination immunization strategies.

DOI 10.1101/2022.02.23.481669

mousebulk RNA-seq

𝕏 PostBluesky

MicrobiologybioRxivJan 31, 2022

Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral vaccine

D. W. Hawman, K. Meade-White, C. Clancy…·J. Erasmus

DOI 10.1016/j.ebiom.2022.104196

mouserat

𝕏 PostBluesky

MicrobiologybioRxivDec 10, 2021

SARS-CoV2 variant-specific replicating RNA vaccines protect from disease and pathology and reduce viral shedding following challenge with heterologous SARS-CoV2 variants of concern

D. W. Hawman, K. Meade-White, J. Archer…·J. Erasmus

This study evaluates a replicating RNA vaccine against SARS-CoV-2 variants, showing protection from disease and reduced viral shedding after heterologous challenge.

DOI 10.7554/elife.75537

mouserat

𝕏 PostBluesky

ImmunologybioRxivPreprintMay 28, 2020

Single-dose replicating RNA vaccine induces neutralizing antibodies against SARS-CoV-2 in nonhuman primates

J. H. Erasmus, A. P. Khandhar, A. C. Walls…·D. H. Fuller

DOI 10.1101/2020.05.28.121640

non-human primateexperimental assay

𝕏 PostBluesky